Clinical outcomes with long-term sorafenib treatment of patients with hepatocellular carcinoma: a multicenter real-life study.
Future Oncol
; 14(29): 3049-3058, 2018 Dec.
Article
em En
| MEDLINE
| ID: mdl-30091371
ABSTRACT
AIM:
This multicenter field-practice study evaluates outcomes of long-term sorafenib in hepatocellular carcinoma (HCC) patients.METHODS:
Consecutive HCC patients on sorafenib were enrolled. We evaluated those receiving sorafenib for ≥12 months.RESULTS:
Out of 800 patients on sorafenib, 81 (10%) received long-term treatment. Median duration of treatment was 22.7 months (range 12.3-92.6). Only 21 (26%) reported grade 3/4 adverse events. Complete response was reported in 11 patients (14%). Median overall survival was 34.8 months (95% CI 29.9-44.3). Only baseline Child-Pugh class was associated with survival.CONCLUSION:
Sorafenib could result in long-term control of HCC in a relevant proportion of patients. Given the availability of regorafenib in the second-line setting, an earlier introduction of systemic therapy may be considered according to clinical indications.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Assistência de Longa Duração
/
Carcinoma Hepatocelular
/
Sorafenibe
/
Neoplasias Hepáticas
/
Antineoplásicos
Idioma:
En
Ano de publicação:
2018
Tipo de documento:
Article